Fouquet, G., Guidez, S., Richez, V., Stoppa, A., Le Tourneau, C., Macro, M., . . . Leleu, X. (2018). Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget.

Fouquet, Guillemette, et al. "Phase I Dose-escalation Study of F50067, a Humanized Anti-CXCR4 Monoclonal Antibody Alone and in Combination With Lenalidomide and Low-dose Dexamethasone, in Relapsed or Refractory Multiple Myeloma." Oncotarget 2018.

Fouquet, Guillemette, et al. "Phase I Dose-escalation Study of F50067, a Humanized Anti-CXCR4 Monoclonal Antibody Alone and in Combination With Lenalidomide and Low-dose Dexamethasone, in Relapsed or Refractory Multiple Myeloma." Oncotarget 2018.